210 related articles for article (PubMed ID: 28782482)
1. Drug Combination in Clinical Cancer Treatments.
Lu DY; Lu TR; Yarla NS; Wu HY; Xu B; Ding J; Zhu H
Rev Recent Clin Trials; 2017; 12(3):202-211. PubMed ID: 28782482
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Drug Combinations, How Far We can Go Through?
Lu DY; Chen EH; Wu HY; Lu TR; Xu B; Ding J
Anticancer Agents Med Chem; 2017; 17(1):21-28. PubMed ID: 27039923
[TBL] [Abstract][Full Text] [Related]
3. Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics.
Lu DY; Qu RX; Lu TR; Wu HY
Rev Recent Clin Trials; 2017; 12(2):101-110. PubMed ID: 28190390
[TBL] [Abstract][Full Text] [Related]
4. Computational oncology--mathematical modelling of drug regimens for precision medicine.
Barbolosi D; Ciccolini J; Lacarelle B; Barlési F; André N
Nat Rev Clin Oncol; 2016 Apr; 13(4):242-54. PubMed ID: 26598946
[TBL] [Abstract][Full Text] [Related]
5. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine in oncology: a personal view with myths and facts.
Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):141-7. PubMed ID: 20406176
[TBL] [Abstract][Full Text] [Related]
8. In silico drug combination discovery for personalized cancer therapy.
Jeon M; Kim S; Park S; Lee H; Kang J
BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
[TBL] [Abstract][Full Text] [Related]
9. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
10. [Cancer stem cells as the therapeutic target of tomorrow].
Hatina J
Wien Med Wochenschr; 2017 Feb; 167(1-2):25-30. PubMed ID: 26943922
[TBL] [Abstract][Full Text] [Related]
11. Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine.
Wang Z; Liu X; Ho RL; Lam CW; Chow MS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399658
[TBL] [Abstract][Full Text] [Related]
12. Drosophila as a novel therapeutic discovery tool for thyroid cancer.
Das T; Cagan R
Thyroid; 2010 Jul; 20(7):689-95. PubMed ID: 20578898
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment and cancer therapy resistance.
Sun Y
Cancer Lett; 2016 Sep; 380(1):205-15. PubMed ID: 26272180
[TBL] [Abstract][Full Text] [Related]
14. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.
Shinko D; Diakos CI; Clarke SJ; Charles KA
Clin Pharmacol Ther; 2017 Oct; 102(4):599-610. PubMed ID: 28699186
[TBL] [Abstract][Full Text] [Related]
16. Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.
Muñoz-Pinedo C; González-Suárez E; Portela A; Gentilella A; Esteller M
Cancer Res; 2013 Jul; 73(14):4185-9. PubMed ID: 23687347
[TBL] [Abstract][Full Text] [Related]
17. At the crossroads of cancer stem cells and targeted therapy resistance.
Wang A; Qu L; Wang L
Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488
[TBL] [Abstract][Full Text] [Related]
18. Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy.
Frei E; Miller D; Clark JR; Fallon BG; Ervin TJ
Recent Results Cancer Res; 1986; 103():1-5. PubMed ID: 3738192
[No Abstract] [Full Text] [Related]
19. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
20. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
Masui K; Gini B; Wykosky J; Zanca C; Mischel PS; Furnari FB; Cavenee WK
Carcinogenesis; 2013 Apr; 34(4):725-38. PubMed ID: 23455378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
